While chetomin (8) was identified as the first naturally occurring antagonist of the C-C chemokine receptor type 2 (CCR2) [90], it has played a significant role in uncovering the mechanisms that contribute to the invasiveness of specific cancer cell types, particularly highlighting the preponderant role of hypoxia in ovarian and triple-negative breast cancers [89,91]. The gene discussed is CCR2; the disease is triple-negative breast carcinoma.